"One in five people treated for a serious form of leishmaniasis in Nepal relapse after a year," Nature reports, adding, "The finding, published in Clinical Infectious Diseases last month, is 'an alarming signal' for campaigns to eliminate the neglected disease, say researchers." The news service notes, "The orally administered drug miltefosine emerged as the treatment of choice a decade ago, taking over from injections of the highly toxic, antimony-based drug sodium stibogluconate, which had started showing failure rates of 65 percent in India's northern state of Bihar." However, "reports are now emerging of miltefosine failure, which scientists worry will narrow down the pipeline of drugs available for treatment," the news service adds.